News | Structural Heart | November 09, 2021

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at two-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at two-years, TAVR was cost-effective for these patients.

Findings were reported at TCT 2021, the 33rd annual scientific symposium of the Cardiovascular Research Foundation (CRF). 

Previous studies have demonstrated that TAVR is cost effective compared with medical therapy for patients with severe aortic stenosis and extreme surgical risk and compared with SAVR for patients at intermediate and high surgical risk. Based on the results from recent trials, including PARTNER 3, TAVR has been approved for low-risk patients in the U.S. Currently, there is little evidence as to whether TAVR is cost effective for low-risk patients.

Between March 2016 and October 2017, 979 patients in the U.S. were enrolled in the PARTNER 3 trial and randomized to either TAVR using the SAPIEN 3 valve (n=492) or SAVR (n=487). Of these, 485 underwent TAVR and 444 underwent SAVR. During the index hospitalization, TAVR resulted in significant reductions in procedure duration (53 versus 198 minutes) as well as ICU (0.7 versus 2.6 days) and non-ICU length of stay (1.2 versus 3.7 days, all p<0.001). Between discharge and six-month follow-up, TAVR also resulted in fewer rehospitalizations and less use of rehabilitation services—benefits that were largely sustained through two years.

Costs were assessed based on a combination of resource utilization (for the initial TAVR and SAVR procedures) and linked Medicare claims for all other costs through two years. In the study population, index hospitalization costs were $47,196 for TAVR and $46,606 for SAVR (a difference of $591). Between hospital discharge and two-years, follow-up costs were less for TAVR compared with SAVR ($19,638 vs. $22,258, a difference of $2,620). Overall, the total combined two-year cost was lower for TAVR versus SAVR ($66,834 vs. $68,864, a difference of $2,030). Two-year quality-adjusted life expectancy was greater with TAVR than SAVR (1.71 vs. 1.66 quality-adjusted life years, p=0.06)—driven by early benefits in both quality of life and survival. Although long-term outcomes are unknown at present, assuming there are no long-term differences in survival or cost, TAVR was projected to be an economically dominant strategy (lower cost, better outcome) with a 95% probability of being cost-effective compared with SAVR

“Data from the PARTNER 3 trial show that for patients with severe aortic stenosis and low surgical risk, TAVR is cost-saving compared with SAVR at two year follow-up and is projected to be highly cost effective over a lifetime horizon-- as long as there are no major differences in late mortality between the two strategies,” said David J. Cohen, M.D., director of clinical and outcomes research, CRF and director of academic affairs for St. Francis Hospital and Heart Center. “Given the importance of long-term outcomes in these projections, extended follow-up through at least 10 years will be critical to validate these findings.”

The study was funded by Edwards Lifesciences Inc. Cohen reported the following disclosures: grant support/research contract (institutional) from Abbott Vascular, Boston Scientific Corporation, Corvia, Edwards Lifesciences, Medtronic, Saranas, Svelte, and Volcano Corporation; consultant fee/honoraria/speaker's bureau (personal) from Abbott Vascular, Boston Scientific Corporation, Edwards Lifesciences, and Medtronic; and grant support/research contract (personal) from Ancora Heart.

 

Links to All the TCT 2021 Late-Breaking Clinical Trials

More structural heart technology news

Related Content

Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Videos | TCT

Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter ...

Home October 04, 2019
Home
Videos | TCT

DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo ...

Home October 03, 2018
Home
Feature | TCT

October 4, 2018 – The Cardiovascular Research Foundation (CRF) had 15 late-breaking trials and 12 late-breaking clinical ...

Home September 21, 2018
Home
Subscribe Now